Literature DB >> 16553361

Canadian consensus guidelines for the diagnosis and management of acromegaly.

Shereen Ezzat1, Omar Serri, Constance L Chik, Michelle D Johnson, Hugues Beauregard, Sorana Marcovitz, B L Gregoire Nyomba, Juan Rivera Ramirez, Ehud Ur.   

Abstract

Acromegaly is a chronic condition associated with considerably increased morbidity and mortality if left unchecked. In December 2004, a national meeting was held to discuss the diversity in clinical practice across the country in diagnosing and treating patients with acromegaly, as well as to seek consensus on a number of management principles. The group reviewed recent guidelines and discussed issues of diagnosis, treatment, monitoring and treating comorbidities to seek a Canadian consensus on the management of this rare disorder. Consensus was that diagnosis should include clinical and biochemical findings, but is hinged on establishing GH hypersecretion with IGF-I and OGTT testing. Treatment has traditionally included surgical resection or debulking, along with adjunctive medical therapy (primarily somatostatin analogues), if necessary, to normalize GH levels. The option of primary medical therapy in managing this condition has recently emerged and can be justified for non-surgical candidates or for those in whom surgery is not expected to be curative. Overall, improved screening practices and superior epidemiological data are required, since timely diagnosis and appropriate treatment are crucial for reducing the potentially debilitating effects of this chronic, progressive disease. The current evidence also supports the need for long-term follow-up of disease activity and comorbidities in diagnosed patients. A national meeting was held to discuss the diversity in clinical practice across the country in diagnosing and treating patients with acromegaly, as well as to seek consensus on a number of management principles. After brief reviews of the most recent Canadian guidelines and the 2004 guidelines published by the American Association of Clinical Endocrinologists, the group was asked to specifically examine the issues of diagnosis, treatment, monitoring and treating comorbidities and seek a Canadian consensus on practice. This paper summarizes the working group's findings and the points of consensus that were achieved.

Entities:  

Mesh:

Year:  2006        PMID: 16553361

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  6 in total

1.  Guidelines versus real life practice: the case of colonoscopy in acromegaly.

Authors:  M Parolin; F Dassie; L Russo; S Mazzocut; M Ferrata; E De Carlo; R Mioni; F Fallo; R Vettor; C Martini; P Maffei
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 2.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

3.  Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases.

Authors:  M S Broder; M P Neary; E Chang; D Cherepanov; L Katznelson
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

4.  Evaluation of Acromegaly patients with sleep disturbance related symptoms.

Authors:  Deniz Celik; Sezgi Sahin Duyar; Funda Aksu; Selma Firat; Bulent Ciftci
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 2.340

5.  Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.

Authors:  Sonia Cheng; Rany Al-Agha; Paula B Araujo; Omar Serri; Sylvia L Asa; Shereen Ezzat
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

6.  Prevalence of acromegaly in patients with symptoms of sleep apnea.

Authors:  Gemma Sesmilo; Eugenia Resmini; Marcel Sambo; Concepción Blanco; Fernando Calvo; Fernando Pazos; Pablo Fernández-Catalina; Purificación Martínez de Icaya; Concepción Páramo; Carmen Fajardo; Mónica Marazuela; Cristina Álvarez-Escolá; Juan Jose Díez; Verónica Perea
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.